Gino Santini

In 2010, Mr. Santini retired from a distinguished career with Eli Lilly and Company that spanned nearly three decades. During his tenure at Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, President of the women’s health franchise and President of U.S. operations. Mr. Santini capped his career at Lilly as a member of the company’s executive committee and as Senior Vice President of Corporate Strategy and Business Development. In addition to Artax, Mr. Santini currently serves on the Board of Directors of Horizon Therapeutics, Intercept Pharmaceuticals, Intarcia Therapeutics, Collegium Pharmaceutical and AMAG Pharmaceuticals. He previously served on the boards of SORIN SpA, Vitae Pharmaceuticals until their acquisitions, and of Allena Pharmaceuticals.

Mr. Santini, fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and an MBA from the University of Rochester.